AKL Research and Development (AKLRD) and Nordic Bioscience Clinical Development, have announced a risk-share agreement to assess the efficacy of a novel, oral medicine, APPA, in a phase II trial of Osteoarthritis (OA). The collaboration was announced at the Osteoarthritis Research Society International (OARSI) World Congress 2019 in Toronto, Canada.
The partnership will assess the effectiveness of APPA both in relieving OA pain and in slowing the destruction of cartilage, which has already been demonstrated in animal studies. OA is a degenerative disease of the joints affecting more than half of all people over the age of 65 and is the third most rapidly rising condition worldwide.
Jeppe Ragnar Andersen, CEO of Copenhagen-based Nordic Bioscience Clinical Development, says: “As experts in applied precision medicine and clinical trials in osteoarthritis, we are keen to assess APPA’s ability to modify disease and regulate the inflammation cascade.
“It is clear to us that APPA has the potential to address the unmet need in OA. APPA is unique because it may not only stop the severe pain caused by OA but also prevent its progression, which can eventually destroys joints. This makes it an exciting possibility in a condition that has few treatment options available, none of which can currently stop further harm from occurring.”
For the full story click here